Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Integrated Clinical Research LLC

Neither a doctor nor a teaching hospital

Research payments

$2,692,952

370 payments

Through program year 2025, Integrated Clinical Research LLC is reported as receiving $2,692,952 in research payments, across 370 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $420,370 138
2024 Research $418,218 22
2023 Research $518,907 44
2022 Research $1,106,474 62
2021 Research $52,713 40
2020 Research $127,380 38
2019 Research $48,891 26

Breakdown

Who paid Research payments · program years 2019–2025
  1. Genentech, Inc. $974,976 39 payments
  2. EyePoint Pharmaceuticals US, Inc. $679,313 6 payments
  3. Hexal AG $216,739 24 payments
  4. Sanofi Pasteur Inc. $154,623 20 payments
  5. Tolmar, Inc. $134,862 106 payments
  6. AstraZeneca Pharmaceuticals LP $92,870 1 payment
  7. AbbVie, Inc. $72,759 40 payments
  8. GlaxoSmithKline, LLC. $62,540 9 payments
  9. Sanofi US Services Inc. $60,938 4 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $60,859 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Wet AMD $609,696 2 payments
  2. Faricimab Dme Long Term Extension Rhone X $469,666 12 payments
  3. Csok583a12301 $216,739 24 payments
  4. A Phase III Study to Evaluate Faricimab in Patients With Central Retinal Vein Occlusion $192,998 4 payments
  5. Open Label Extension Study to Evaluate the Long Term Safety of Faricimab in Patients With Namd $97,969 6 payments
  6. A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers $94,842 7 payments
  7. a phase third,randomised,double blind,placebo controlled,eventdriven study to evaluate the effect of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on the risk of incident heart failure and cardiovascular death in participants with increased risk of reveloping heart failure $92,870 1 payment
  8. Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) $92,212 10 payments
  9. Study of the Port Delivery System With Ranibizumab in Patients With Diabetic MacUlar Edema $88,985 5 payments
  10. Tol-Clar-20024 $87,184 98 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record